Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 4/20 | 0.79 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.79 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.79 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | DGKA | P23743 | 1/20 | 0.57 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL528141 | 1.00 | PRKCA (0.79) | PRKCAPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL15011314 | 1.00 | PRKCA (0.79) | PRKCAPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL1924789 | 1.00 | PRKCA (0.79) | PRKCAPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL6430499 | 0.98 | PRKCA (0.76) | PRKCAPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL528434 | 0.91 | PRKCA (0.82) | PRKCAPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL23668326 | 0.88 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL3779835 | 0.88 | PRKCA (0.77) | PRKCAPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL8049183 | 0.88 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL23500683 | 0.88 | PRKCA (0.77) | PRKCAPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL2502820 | 0.88 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3554263-A1 | COMPOSITIONS AND METHODS THAT MODULATE DIGESTIBILITY IN A COMPANION ANIMAL | Société des Produits Nestlé S.A. (CH) | 2019-10-23 | — | — | EP | claimed |
| WO-2018109664-A1 | COMPOSITIONS AND METHODS THAT MODULATE DIGESTIBILITY IN A COMPANION ANIMAL | NESTEC SA (CH) | 2018-06-21 | — | — | WO | claimed |
| EP-3554255-A1 | COMPOSITIONS AND METHODS THAT MODULATE CHOLESTEROL IN A COMPANION ANIMAL | Société des Produits Nestlé S.A. (CH) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018109666-A1 | COMPOSITIONS AND METHODS THAT MODULATE CHOLESTEROL IN A COMPANION ANIMAL | NESTEC SA (CH) | 2018-06-21 | — | — | WO | disclosed |
| EP-2930512-B1 | Biomarkers for fatty liver disease and methods using the same | METABOLON INC (US) | 2018-01-31 | — | — | EP | disclosed |
| US-9486481-B2 | Method of modulating fatty acid mobilization and oxidation | REOXCYN DISCOVERIES GROUP, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| EP-2930512-A2 | Biomarkers for fatty liver disease and methods using the same | Metabolon Inc. (US) | 2015-10-14 | — | — | EP | disclosed |
| EP-2546649-B1 | Biomarkers for fatty liver disease and methods using the same | METABOLON INC (US) | 2015-02-25 | — | — | EP | disclosed |
| EP-2788763-A2 | BIOMARKERS FOR KIDNEY CANCER AND METHODS USING THE SAME | Metabolon, Inc. (US) | 2014-10-15 | — | — | EP | disclosed |
| WO-2013086365-A2 | BIOMARKERS FOR KIDNEY CANCER AND METHODS USING THE SAME | METABOLON, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| EP-2227689-B1 | BIOMARKERS FOR FATTY LIVER DISEASE AND METHODS USING THE SAME | METABOLON INC (US) | 2012-12-26 | — | — | EP | disclosed |
| US-20120003158-A1 | Biomarkers for Inflammatory Bowel Disease and Methods Using the Same | METABOLON, INC. | 2012-01-05 | — | — | US | disclosed |